[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE399777T1 - Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors - Google Patents

Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Info

Publication number
ATE399777T1
ATE399777T1 AT04749150T AT04749150T ATE399777T1 AT E399777 T1 ATE399777 T1 AT E399777T1 AT 04749150 T AT04749150 T AT 04749150T AT 04749150 T AT04749150 T AT 04749150T AT E399777 T1 ATE399777 T1 AT E399777T1
Authority
AT
Austria
Prior art keywords
pyrrole
modulators
liver
receptor
dione derivatives
Prior art date
Application number
AT04749150T
Other languages
English (en)
Inventor
Jonas Bostroem
Kay Brickmann
Patrik Holm
Pernilla Sandberg
Marianne Swanson
Christer Westerlund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE399777T1 publication Critical patent/ATE399777T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT04749150T 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors ATE399777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE399777T1 true ATE399777T1 (de) 2008-07-15

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749150T ATE399777T1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Country Status (26)

Country Link
US (1) US7432288B2 (de)
EP (1) EP1646626B1 (de)
JP (1) JP2007521312A (de)
KR (1) KR20060035748A (de)
CN (1) CN1823061A (de)
AR (1) AR045721A1 (de)
AT (1) ATE399777T1 (de)
AU (1) AU2004255999B2 (de)
BR (1) BRPI0412472A (de)
CA (1) CA2532056A1 (de)
DE (1) DE602004014773D1 (de)
ES (1) ES2308204T3 (de)
GB (1) GB0316232D0 (de)
HK (1) HK1088320A1 (de)
IL (1) IL172760A0 (de)
IS (1) IS8293A (de)
MX (1) MXPA06000414A (de)
MY (1) MY135821A (de)
NO (1) NO20060081L (de)
RU (1) RU2006102130A (de)
SA (1) SA04250204B1 (de)
TW (1) TW200503691A (de)
UA (1) UA82109C2 (de)
UY (1) UY28408A1 (de)
WO (1) WO2005005417A1 (de)
ZA (1) ZA200600222B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (de) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mischung und Verbindungen von Mycelien von Antrodia Camphorata und deren Verwendung
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
JP2008526841A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓x受容体調節因子としてのイソチアゾール−3(2h)−オン1,1−ジオキシドのアニリン系誘導体
CA2640806A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
KR20110029161A (ko) 2008-07-01 2011-03-22 제넨테크, 인크. Mek 키나제 억제제로서의 비시클릭 헤테로사이클
RU2495028C2 (ru) 2008-07-01 2013-10-10 Дженентек, Инк. Изоиндолоны и способы их применения
RU2013115395A (ru) 2010-09-07 2014-10-20 СНУ Ар энд ДиБи ФАУНДЕЙШН Сестертерпеновое соединение и его применение
JP2014500264A (ja) 2010-12-03 2014-01-09 アラーガン インコーポレイテッド スフィンゴシン−1−リン酸(s1p)受容体モジュレーターとしての新規オキシム誘導体
WO2012074780A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US11648220B2 (en) 2016-01-11 2023-05-16 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
EP4073025B1 (de) 2019-12-13 2024-03-27 Inspirna, Inc. Metallsalze und verwendungen davon
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006564A1 (fr) 1998-07-30 2000-02-10 Japan Tobacco Inc. Composes de maleimide disubstitues et utilisation en medecine de ces derniers
ES2234300T3 (es) 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
EP1212065A4 (de) 1999-07-08 2004-02-11 Tularik Inc Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
HK1088320A1 (en) 2006-11-03
KR20060035748A (ko) 2006-04-26
WO2005005417A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
EP1646626B1 (de) 2008-07-02
AU2004255999A1 (en) 2005-01-20
JP2007521312A (ja) 2007-08-02
DE602004014773D1 (de) 2008-08-14
RU2006102130A (ru) 2007-08-20
MXPA06000414A (es) 2006-03-17
ES2308204T3 (es) 2008-12-01
ZA200600222B (en) 2007-04-25
SA04250204B1 (ar) 2008-03-23
CN1823061A (zh) 2006-08-23
IL172760A0 (en) 2006-04-10
MY135821A (en) 2008-07-31
TW200503691A (en) 2005-02-01
CA2532056A1 (en) 2005-01-20
US20060235015A1 (en) 2006-10-19
IS8293A (is) 2006-02-09
EP1646626A1 (de) 2006-04-19
GB0316232D0 (en) 2003-08-13
AR045721A1 (es) 2005-11-09
UY28408A1 (es) 2005-02-28
UA82109C2 (uk) 2008-03-11
US7432288B2 (en) 2008-10-07
NO20060081L (no) 2006-02-08
BRPI0412472A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
HK1088320A1 (en) Pyrrole-2, 5-dione derivatives as liver x receptor modulators
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
HK1088318A1 (en) Pyrrole-2, 5-dithione derivatives as liver x receptor modulators
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE420881T1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
MA28391B1 (fr) Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
IL180630A0 (en) Pyrrole derivatives as pharmaceutical agents
DE60317630D1 (de) Indol, azaindol und verwandte heterocyclische pyrrolidin-derivate
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden
ZA200804349B (en) 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
AU2003205964A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
SI1828154T1 (sl) Derivati fenil-piperazin metanona
AU2003214520A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
AU2003223010A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003278403A1 (en) 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist
ATE398620T1 (de) Spirokondensierte indolinderivate als pestizide
DE602004009583D1 (de) Piperidin- oder 8-azabicycloä3.2.1üoct-3-ylderivate, die sich als modulatoren der chemokinrezeptoraktivität eignen
AP2005003425A0 (en) Heterobicyclic compounds used as fungicides.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties